Drugs / Tulmimetostat
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05942300 | Jan 2024 → Jul 2028 expected | ovarian cancer | Lan Coffman | Recruiting | No outcome recorded |
| Phase 1 | NCT05944562 | Jan 2024 → Feb 2027 expected | Sezary syndrome, mycosis fungoides | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT07190300 | Jan 2026 → Aug 2032 expected | prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05467748 | Dec 2025 → Dec 2027 expected | non-small cell lung carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07206056 | Oct 2025 → Nov 2029 expected | castration-resistant prostate carcinoma | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04104776 | Sep 2019 → Feb 2030 expected | T-cell non-Hodgkin lymphoma, castration-resistant prostate carcinoma, diffuse large B-cell lymphoma, endometrial cancer +2 | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tulmimetostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05944562 ↗ |
| Known as | CPI-0209 | “The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of...” NCT04104776 ↗ |
| Action | Inhibit | “EZH2 inhibitor” NCT05467748 ↗ |
| Modality | Small molecule | — CHEMBL5095231 ↗ |
| Route | Oral | “Tulmimetostat dosed once per day orally in 28 day cycles” NCT04104776 ↗ |
| Target | EZH2 | “EZH2 inhibitor” NCT05467748 ↗ |